Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas

The BRAFV600E mutation, which in melanoma is targetable with vemurafenib, is also found in sarcomas and we here evaluate the therapeutic potential in sarcoma cell lines. Methods: Four sarcoma cell lines harboring the BRAFV600E mutation, representing liposarcomas (SA-4 and SW872), Ewing sarcoma (A673...

Full description

Bibliographic Details
Main Authors: Sarina Gouravan, Leonardo A. Meza-Zepeda, Ola Myklebost, Eva W. Stratford, Else Munthe
Format: Article
Language:English
Published: MDPI AG 2018-03-01
Series:International Journal of Molecular Sciences
Subjects:
BRAF
precision medicine
drug repurposing
Online Access:http://www.mdpi.com/1422-0067/19/4/969

Internet

http://www.mdpi.com/1422-0067/19/4/969

Similar Items